Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a ...

Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first ...

A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

Philips has begun rolling out a major update to its cardiovascular ultrasound systems, incorporating a host of imaging ...

The personalized orthopedic implant maker restor3d has raised a total of $104 million to boost its commercial plans across ...

Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for ...

Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on ...

Chinese contract research and manufacturing outfit ChemPartner is building out its U.S. footprint in the heart of the ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its ...

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

Amid a frozen-over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...